Tonix Pharmaceuticals (TNXP) said it has received a target action data of Aug. 15, 2025, for the application of its ...

Click here for a 6-minute video of Seth Lederman, MD, reviewing the status of TNX 102-SL for fibromyalgia Opioids come with their own set of problems. Opioids can be addictive and, over time ...

TNX-102 SL is a non-opioid, centrally-acting analgesic administered at bedtime for the treatment of fibromyalgia. The Food ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for TNX-102 SL, a non-opioid, centrally acting ...

Tonix Pharmaceuticals (TNXP) announced that the U.S. Food and Drug Administration, FDA, assigned a Prescription Drug User Fee Act, PDUFA, goal ...

Tonix Pharmaceuticals announced the FDA’s acceptance of its New Drug Application for TNX-102 SL, a non-opioid analgesic for fibromyalgia. This acceptance marks potential progress toward ...

If the NDA is accepted, Tonix said the FDA could commit to a decision on approval in 2025, which means TNX-102 SL could be on the market as early as next year, giving fibromyalgia sufferers a much ...

If the NDA is accepted, Tonix said the FDA could commit to a decision on approval in 2025, which means TNX-102 SL could be on the market as early as next year, giving fibromyalgia sufferers a ...